First Racial-Ethnic Breast and Cervical Cancer Screening Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

WASHINGTON—A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

Specifically, 4.4% of AI/AN women, 3.2% of blacks, 3.0% of whites, 2.7% of Hispanics, and 1.9% of Asian and Pacific Islanders (A/PIs) had abnormal tests. Biopsies detected serious cervical lesions in 9.9 per 1,000 Pap tests among whites, followed by Hispanics with 7.6 per 1,000, blacks at 7.1 per 1,000, AI/AN women with 6.7 per 1,000, and A/PIs at 5.4 per 1,000 Pap tests.

AI/AN women were the least likely to have ever had a Pap test prior to participating in a NBCCEDP screening. Black women were the least likely to receive follow-up care after a diagnosis of a serious cervical lesion.

NBCCEDP, which is administered by the CDC, is a federally funded program that provides breast and cervical cancer screenings to older and low-income women, and underserved women of racial and ethnic minority groups.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Related Content